Clonal Distribution of Invasive Pneumococci, Czech Republic, 1996–2003

Helena Žemličková, Pavla Urbášková, Vladislav Jakubů, Jitka Motlová, Martin Musílek, and Bohumír Procházka

We conducted surveillance on invasive pneumococci isolated from adults in the Czech Republic during 1996–2003. The 7 most prevalent serotypes were characterized. Coverage with the 7-valent pneumococcal conjugate vaccine was low. Our observations confirm that detection methods may have modified the expected effect of this vaccine.

Streptococcus pneumoniae is a leading cause of illness and death in children and adults (1,2). The incidence of invasive pneumococcal disease (IPD) has been reduced by a 7-valent pneumococcal conjugate vaccine (PCV7) (3). Although certain serotypes of S. pneumoniae are recognized among children, adults carry a wider range of serotypes (4). Several studies have reported cases of IPD in adults caused by common childhood serotypes (5,6). The causes of such cases are unclear, but use of antimicrobial drugs (6), progressive population aging (5), and modifications to blood culture protocols have been suggested (7). PCV7 efficacy in children has raised the question of whether to use PCV7 in elderly persons (5).

In the Czech Republic, patients in follow-up care departments (i.e., <1% of the adult population), have been vaccinated with a 23-valent polysaccharide vaccine since 2001. PCV7 showed a reported 66% serotype coverage in children (8) and has been included in the routine childhood immunization program since January 2009.

Clones associated with IPD have been characterized by genotyping. Use of PCV7 exerts selective pressure against vaccine serotypes. Clonality data obtained before vaccine use will make it possible to demonstrate future changes in the genetic structure of pneumococci. Therefore, the purpose of our study was to identify IPD serotype distribution and clonality in adults in the Czech Republic before the use of PCV7.

The Study

Invasive pneumococcal isolates from adults ≥18 years of age were obtained from blood (n = 460) and cerebrospinal fluid (CSF) (n = 229) during 1996–2003 by 54 laboratories serving ≈85% of the population in the Czech Republic. Isolates were serotyped by using the Quellung reaction (9). Antimicrobial drug susceptibility and MICs were determined by the broth microdilution method according to Clinical and Laboratory Standards Institute recommendations (10). Genotyping was performed by using pulsed-field gel electrophoresis (PFGE) (11) and multilocus sequence typing (MLST) (12). MLST results were identical between isolates of the same serotype within a PFGE subtype (13). Cluster analyses were based on allelic data that used the eBURST algorithm (14). Numerical trend was evaluated by regression analysis of the logarithm of the number of isolates by using SPSS for Windows version 14 (SPSS, Inc., Chicago, IL, USA). The χ² test for trend (Epi Info version 3.4; Centers for Disease Control and Prevention, Atlanta, GA, USA) was used to evaluate variations in proportions of different serotypes; p values <0.05 were considered significant.

During 1996–2003, a total of 446 (64.7%) isolates were obtained from adults 18–64 years of age and 243 (35.3%) isolates were obtained from adults ≥65 years of age. A progressive increase in recovery of isolates from blood was observed from 44 during 1996–1997 to 199 during 2002–2003 (p = 0.009) (Figure 1). Serotyping identified 48 serotypes; 10 of these serotypes included ≥30 isolates. Half of all strains belonged to serotypes 3 (12.7%), 4 (8.6%), 8 (7%), 1 (5.8%), 19F (5.5%), 14 (5.5%), and 9V (5.2%) (Figure 2). Serotype coverage rates by PCV7, PCV10, PCV13, and 23-valent polysaccharide vaccine were 32.5%, 44.2%, 62.3%, and 82.1%, respectively, among adults 18–64 years of age and 35.4%, 42.8%, 61.3%, and 85.6%, respectively, among adults ≥65 years of age.

Serotype distribution did not vary significantly with age group and type of isolate, except for serotype 1, which was more common (p = 0.037) among younger adults (18–64 years) and more prevalent in blood (p = 0.004). With the exception of 1998–1999, serotype 3 was most common identified. This serotype, which composed 11% of all isolates during 1996–2001, increased to 15% during 2002–2003 (p = 0.289). A change was also observed in the proportions of serotypes 1 and 4 (Figure 1). Serotype 1 increased from 6% during 1996–1997 to 17% during 1998–1999 (p = 0.027) and then decreased to 3% during 2002–2003 (p<0.001). Serotype 4 increased from 2% during 1996–1997 to 13% during 2002–2003 (p=0.001) (Figure 1).

Penicillin-resistant pneumococci were uncommon (range 1%–5%), and no isolate showed high resistance to penicillin (MIC >1 mg/L). Resistance to chloramphenicol decreased from 5% during 1996–1997 to 2% during 2002–
2003 (p = 0.114). Tetracycline resistance also decreased from 8% during 1996–1997 to 6% during 2002–2003 (p = 0.732). Few (<9) isolates were resistant to erythromycin. Antimicrobial drug resistance was associated with certain serotypes. Eighteen of 23 penicillin-resistant pneumococci isolates belonged to serotype 9V. Resistance to chloramphenicol, usually observed with resistance to tetracycline, was seen most often in serotype 19F isolates.

Of 347 isolates of the 7 most common serotypes, 335 were characterized by PFGE and 130 PFGE subtypes were analyzed by MLST (online Appendix Table, www.cdc.gov/EID/content/16/2/287-appT.htm). Forty-six allelic profiles were identified, 18 of which carried new alleles (n = 11) or novel combinations of known alleles (n = 7). Of 10 new alleles, 5 belonged to serotype 4. The gdh128 allele was identified in serotype 4 and 9V isolates. Until recently, only gdh128 was found among isolates from other countries. At least 60% of isolates of serotypes 1, 3, 9V, 14, and 19F have been identified within clones in the Pneumococcal Molecular Epidemiology Network. In contrast, only 25% of serotype 4 and 8 isolates were identified in this network, and these serotypes consisted of larger clusters unrelated to global clones.

Conclusions

When we compared our results with those of a study from the United States (5), where 51% of IPD was among elderly persons before introduction of PCV7 and caused by pediatric serotypes (6B, 9V, 14, 19F, and 23F) (5), our data showed a low frequency (27.2%) of pediatric serotypes in older adults. The low frequency of penicillin-nonsusceptible pneumococci isolates of pediatric serotypes explains the observed predominance of drug-susceptible serotypes. Local differences in blood culture protocols could also bias the serotype distribution (7). Although the number of blood cultures performed in the Czech Republic is increasing, lower numbers of invasive pneumococci have been isolated than in other countries in Europe (www.rivm.nl/earss).

The observed predominance of serotype 3, previously reported as less invasive but associated with a high death rate (15), could be explained by sample collection primarily from the most severe IPD cases. In 1998, an increase in serotype 1 invasive disease was reported in Sweden. In our study, serotype 1 was the most common during the
same period. Subsequently, the frequency of this serotype decreased but the frequency of bacteremia increased. The gradual increase in bacteremia and increased frequency of serotype 4, previously found to be moderately invasive (7), could be ascribed to the increase in blood cultures that facilitated detection of moderate disease caused by serotype 4 rather than dissemination of a specific invasive clone because the isolates showed high genotypic diversity. In our collection of invasive strains, the frequency of antimicrobial drug-resistant global clones, all previously found in the Czech Republic (13), varied between serotypes.

Our results support the need for IPD surveillance because differences in detection methods might modify the effect of the vaccine. Continued surveillance will be helpful in detecting any shift in the distribution of invasive serotypes and clones circulating in the Czech Republic and in monitoring the effect of PCV7 on serotype frequencies and the genetic structure of pneumococci.

Acknowledgments

We thank the regional microbiology laboratories for providing pneumococcal isolates.

This study was partly supported by contract LSHM-CT-2003-503413 (Pneumococcal Resistance Epidemicity and Virulence-an International Study) from the European Commission. This publication made use of the MLST website (www.mlst.net) at Imperial College London developed by David Aanensen and funded by the Wellcome Trust.

Dr Žemličková is head of the Czech National Collection of Type Cultures, National Institute of Public Health, Prague, Czech Republic. Her primary research interest is typing of gram-positive bacteria, particularly *S. pneumoniae* and methicillin-resistant *Staphylococcus aureus*.

References

1. Williams BG, Gouws E, Boschi-Pinto C, Bryce J, Dye C. Estimates of world-wide distribution of child deaths from acute respiratory infections. Lancet Infect Dis. 2002;2:25–32. DOI: 10.1016/S1473-3099(01)00170-0
2. Marrie TJ. Community-acquired pneumonia in the elderly. Clin Infect Dis. 2000;31:1066–78. DOI: 10.1086/318124
3. Center KJ. Prevenar vaccination: review of the global data, 2006. Vaccine. 2007;25:3085–9. DOI: 10.1016/j.vaccine.2007.01.021
4. Hausdorff WP, Bryant J, Paradiso PR, Siber GR. Which pneumococcal serogroups cause the most invasive disease: implications for conjugate vaccine formulation and use, part I. Clin Infect Dis. 2000;30:100–21. DOI: 10.1086/313608
5. Feikin DR, Klugman KP, Facklam RR, Zell ER, Schuchat A, Whitney CG, et al. Increased prevalence of pediatric pneumococcal serotypes in elderly adults. Clin Infect Dis. 2005;41:481–7. DOI: 10.1086/432015
6. Kronenberg A, Zucs P, Droz S, Mühlmann K. Distribution and invasiveness of *Streptococcus pneumoniae* serotypes in Switzerland, a country with low antibiotic selection pressure, from 2001 to 2004. J Clin Microbiol. 2006;44:2032–8. DOI: 10.1128/JCM.00275-06
7. Hausdorff WP, Siber G, Paradiso PR. Geographical differences in invasive pneumococcal disease rates and serotype frequency in young children. Lancet. 2001;357:950–2. DOI: 10.1016/S0140-6736(00)04222-7
8. Motlova J, Benes C, Kriz P. Incidence of invasive pneumococcal disease in the Czech Republic and serotype coverage by vaccines, 1997–2006. Epidemiol Infect. 2009;137:562–9. DOI: 10.1017/ S0950268808001301
9. Sorensen UB. Typing of pneumococci by using 12 pooled antisera. J Clin Microbiol. 1993;31:2097–100.
10. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing. M100–S17. Wayne (PA): The Institute; 2007.
11. Soares S, Kristinsson KG, Muser JM, Tomasz A. Evidence for the introduction of a multiresistant clone of serotype 6B *Streptococcus pneumoniae* from Spain to Iceland in the late 1980s. J Infect Dis. 1993;168:158–63.
12. Enright MC, Spratt BG. A multilocus sequence typing scheme for *Streptococcus pneumoniae*: identification of clones associated with serious invasive disease. Microbiology. 1998;144:3049–60. DOI: 10.1099/00221287-144-11-3049
13. Žemličková H, Melter O, Urbášková P. Epidemiological relationships among penicillin non-susceptible *Streptococcus pneumoniae* strains recovered in the Czech Republic. J Med Microbiol. 2006;55:437–42. DOI: 10.1099/jmm.0.46270-0
14. Feil EJ, Li BC, Aanensen DM, Hanage WP, Spratt BG. eBURST: inferring patterns of evolutionary descent among clusters of related bacterial genotypes from multilocus sequence typing data. J Bacteriol. 2004;186:1518–30. DOI: 10.1128/JB.186.5.1518-1530.2004
15. Alance SR, McGee L, Jackson D, Chiuo CC, Feldman C, Morris AJ, et al. Association of serotypes of *Streptococcus pneumoniae* with disease severity and outcome in adults: an international study. Clin Infect Dis. 2007;45:46–51. DOI: 10.1086/518538

Address for correspondence: Helena Žemličková, National Institute of Public Health, Šrobárova 48, 100 42 Prague 10, Czech Republic; email: hzemlickova@szu.cz
| Serotype | No. isolates in PFGE type | PFGE type | No. isolates selected for MLST | MLST allelic profile | Estimated % isolates in cluster (no. isolates) | Antimicrobial drug resistance profile of isolates sharing the same ST | PMEN clone name |
|----------|---------------------------|-----------|--------------------------------|----------------------|-----------------------------------------------|---------------------------------------------------------------|----------------|
| 3        | 85                        | 3_1       | 83                             | 180                  | 60 (50)                                       | S S S S S                                                    | Netherlands 31 |
| 4        | 58                        | 4_1       | 17                             | 800                  | 29 (17)                                       | S S S S S                                                    | Sweden 38 |
|          |                           |           |                                | 801                  |                                               | S S S S S                                                    |                |
|          |                           |           |                                | 2361                 |                                               | S S S S S                                                    |                |
|          |                           |           |                                | 2617                 |                                               | S S S S S                                                    |                |
|          |                           |           |                                | 4_2                  | 24 (14)                                       | S S S S S                                                    |                |
|          |                           |           |                                | 205                  |                                               | S S S S S                                                    |                |
|          |                           |           |                                | 2333                 |                                               | S S S S S                                                    | Sweden |
|          |                           |           |                                | 2388                 |                                               | S S S S S                                                    |                |
|          |                           |           |                                | 1022                 |                                               | S S S S S                                                    |                |
|          |                           |           |                                | 4_3                  | 12 (7)                                        | S S S S S                                                    |                |
|          |                           |           |                                | 247                  |                                               | S S S S S                                                    |                |
|          |                           |           |                                | 2342                 |                                               | S S S S S                                                    |                |
|          |                           |           |                                | 2362                 |                                               | S S S S S                                                    |                |
|          |                           |           |                                | 2389                 |                                               | S S S S S                                                    |                |
|          |                           |           |                                | 4_4                  | 16 (9)                                        | S S S S S                                                    |                |
|          |                           |           |                                | 1022                 |                                               | S S S S S                                                    |                |
|          |                           |           |                                | 4_5                  | 3 (2)                                         | S S S S S                                                    |                |
|          |                           |           |                                | 2333                 |                                               | S S S S S                                                    |                |
|          |                           |           |                                | 2546                 |                                               | S S S S S                                                    |                |
|          |                           |           |                                | 6_4                  |                                               | S S S S S                                                    |                |
|          |                           |           |                                | 2_4                  |                                               | S S S S S                                                    |                |
|          |                           |           |                                | 2341                 |                                               | S S S S S                                                    |                |
|          |                           |           |                                | 2341                 |                                               | S S S S S                                                    |                |
|          |                           |           |                                | 4_9                  |                                               | S S S S S                                                    |                |
|          |                           |           |                                | 1637                 |                                               | S S S S S                                                    |                |
| 8        | 46                        | 8_1       | 17                             | 404                  | 78 (36)                                       | S S S S S                                                    | Netherlands 33 |
|          |                           |           |                                | 8_2                  |                                               | S S S S S                                                    |                |
|          |                           |           |                                | 304                  |                                               | S S S S S                                                    | Sweden 40     |
|          |                           |           |                                | 305                  |                                               | S S S R                                                      |                |
|          |                           |           |                                | 306                  |                                               | S S S S                                                    | Sweden 28     |
### Table 1

| 13 | 1  | 2028 | 1  | 7 | 31 | 4 | 34 | 6 | 94 | 3 | (1) | S | S | S | S | S | S |
|----|----|------|----|----|----|---|----|---|----|---|----|---|---|---|---|---|---|
| 19F | 36 | 19F_1 | 30 | 423 | 3 | 1 | 5 | 4 | 12 | 5 | 3 | 8 | 83 (30) | S | S | R\((23)\)/S | R\((22)\)/S | R\((2)\)/S |
| 2024 | 1 | 1 | 5 | 141 | 12 | 5 | 3 | 8 | | | | | | | | |
| 1960 | 1 | 1 | 5 | 4 | 6 | 5 | 3 | 8 | | | | | | | | | |
| 19F_2 | 1 | 271 | 1 | 4 | 16 | 19 | 15 | 6 | 20 | 26 | 3 (1) | I | R | S | R | R |
| 19F_3 | 1 | 2030 | 1 | 8 | 10 | 9 | 8 | 17 | 1 | 17 | 3 (1) | S | S | S | S | S |
| 19F_4 | 2 | 251 | 1 | 18 | 2 | 22 | 1 | 9 | 23 | 14 | 8 (3) | S | S | S | S | R\((1)\)/S |
| 19F_5 | 1 | 251 | 1 | 18 | 2 | 22 | 1 | 9 | 23 | 14 | | | | | | |
| 19F_6 | 1 | 1551 | 1 | 5 | 7 | 4 | 2 | 10 | 1 | 6 | 3 (1) | S | S | S | S | S |

| 14 | 38 | 14_1 | 37 | 124 | 14 | 7 | 5 | 1 | 8 | 14 | 11 | 14 | 97 (37) | S | S | S | S | S | S | Netherlands\(^{\dagger}\) |

| 14_5 | 1 | 1772 | 1 | 8 | 37 | 4 | 5 | 1 | 3 | 8 | 3 (1) | I | R\((1)\)/S | S | S | S | R |

| 9V | 35 | 9V_1 | 26 | 156 | 10 | 7 | 11 | 10 | 1 | 6 | 8 | 1 | 77 (27) | I | R\((1)\)/S | S | S | S | R | Spain\(^{\dagger}\)-3 |

| 162 | 3 | 7 | 11 | 10 | 1 | 6 | 8 | 14 | | | S | S | S | S | R\((3)\)/S |
| 2025 | 1 | 88 | 11 | 10 | 1 | 6 | 8 | 14 | | | S | S | S | S | R |
| 2026 | 1 | 7 | 128 | 10 | 1 | 6 | 8 | 14 | | S | S | S | S | S |
| 9V_4 | 1 | 162 | 1 | 7 | 11 | 10 | 1 | 6 | 8 | 14 | S | R | S | S | R |
| 9V_2 | 8 | 239 | 4 | 15 | 17 | 4 | 16 | 6 | 19 | 17 | 23 (8) | S | S | S | S | R\((6)\)/S |
| 1779 | 1 | 15 | 17 | 4 | 16 | 6 | 19 | 17 | S | S | S | S | S | S | R |

*PFGE, pulsed-field gel electrophoresis; ST, sequence type; MLST, multilocus sequence typing; *aroE*, shikimate dehydrogenase; *gdh*, glucose-6-phosphate dehydrogenase; *gki*, glucose kinase; *recP*, transketose; *spi*, signal peptidase I; *xpt*, xanthine phosphoribosyltransferase; *ddl*, D-alanine-D-alanine ligase; Pen, penicillin; Ery, erythromycin; Cmp, chloramphenicol; Tet, tetracycline; Cot, cotrimoxazole; PMEN, Pneumococcal Molecular Epidemiology Network; S, susceptible; R, resistant. New sequence types and new alleles are shown in **boldface**.

†Defined by e-BURST.